Novo Nordisk | NVO - Gross Profit On Sales


Novo Nordisk reported DKK83.22B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
ANI Pharmaceuticals USD 143.88M 19.7M Mar/2026
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Bausch Health Companies USD 2.08B 294M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Novo Nordisk DKK 83.22B 19.21B Mar/2026
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 136.19M 10.11M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
Zoetis USD 1.76B 140M Jun/2026